AIMD · Ainos, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $161 | - | $2.2K | $4.7K | $106.2K | - | - | - | $20.7K | - |
| Cost of Revenue | $763 | - | $477 | $937 | $18.2K | - | $547 | $25.4K | $26.8K | - |
| Gross Profit | ($602) | - | $1.7K | $3.7K | $88.0K | - | ($547) | ($25.4K) | ($6.0K) | - |
| R&D | $1.69M | - | $1.99M | $1.91M | $1.72M | - | $2.02M | $1.98M | $2.08M | - |
| SG&A | $593.2K | - | $795.3K | $1.84M | $1.53M | - | $1.02M | $1.04M | $1.03M | - |
| Total Operating Expenses | $2.28M | - | $2.79M | $3.75M | $3.25M | - | $3.04M | $3.02M | $3.11M | - |
| D&A | $1.17M | - | - | - | $1.18M | - | - | - | $1.20M | - |
| Operating Income | ($2.28M) | - | ($2.78M) | ($3.75M) | ($3.16M) | - | ($3.04M) | ($3.05M) | ($3.12M) | - |
| Interest Expense | $176.9K | - | $176.6K | $178.0K | $48.7K | - | $44.3K | $40.3K | $48.7K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.46M) | - | ($2.93M) | ($4.08M) | ($3.29M) | - | ($3.70M) | ($3.20M) | ($3.31M) | - |
| EPS - Basic | ($0.41) | - | ($0.64) | ($0.99) | ($1.05) | - | ($1.65) | ($2.45) | ($2.85) | - |
| EPS - Diluted | ($0.41) | - | ($0.64) | ($0.99) | ($1.05) | - | ($3.65) | ($2.45) | ($2.85) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.84M | $417.4K | $1.13M | $1.22M | $2.63M | $3.89M | $5.16M | $8.01M | $1.03M | $1.89M |
| Accounts Receivable | $23 | $22 | $62 | $187 | $91 | $56 | - | $9 | $4.2K | $455 |
| Inventory | $315.6K | $295.6K | $166.9K | $160.1K | $141.8K | $143.8K | $160.7K | $166.3K | $169.7K | $167.6K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $3.52M | $1.14M | $1.72M | $1.73M | $3.05M | $4.34M | $5.65M | $8.47M | $1.51M | $2.47M |
| Total Assets | $22.08M | $20.87M | $22.68M | $23.92M | $26.35M | $28.82M | $31.37M | $35.54M | $29.75M | $31.84M |
| Current Liabilities | $6.35M | $1.08M | $581.4K | $602.8K | $1.52M | $3.95M | $4.13M | $5.74M | $4.71M | $1.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.39M | $13.31M | $12.63M | $12.48M | $13.23M | $13.30M | $13.35M | $14.83M | $7.08M | $7.39M |
| Stockholders' Equity | $5.69M | $7.56M | $10.04M | $11.44M | $13.12M | $15.52M | $18.02M | $20.71M | $22.68M | $24.45M |
| Retained Earnings | ($69.98M) | ($67.52M) | ($63.05M) | ($60.12M) | ($56.04M) | ($52.75M) | ($48.10M) | ($44.40M) | ($41.20M) | ($37.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($983.4K) | - | - | - | ($1.22M) | - | - | - | ($1.49M) | - |
| Investing Cash Flow | ($79) | - | - | - | ($20.6K) | - | - | - | ($111.3K) | - |
| Financing Cash Flow | $3.41M | - | - | - | $14.6K | - | - | - | $777.5K | - |
| CapEx | $8.5K | - | - | - | $33.6K | - | - | - | $4.4K | - |
| Free Cash Flow | ($992.0K) | - | - | - | ($1.26M) | - | - | - | ($1.50M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -373.9% | - | 78.0% | 79.9% | 82.8% | - | - | - | -29.1% | - |
| Operating margin | -1418414.3% | - | -128481.4% | -80327.8% | -2978.0% | - | - | - | -15051.8% | - |
| EBITDA margin | -689175.8% | - | - | - | -1869.6% | - | - | - | -9257.5% | - |
| Net margin | -1527826.1% | - | -135288.5% | -87604.3% | -3094.0% | - | - | - | -15991.2% | - |
| Free cash flow margin | -616126.1% | - | - | - | -1184.7% | - | - | - | -7232.3% | - |
| FCF / Net income | 0.40 | - | - | - | 0.38 | - | - | - | 0.45 | - |
| R&D / Revenue | 1049602.5% | - | 91861.1% | 40999.4% | 1623.3% | - | - | - | 10056.7% | - |
| SG&A / Revenue | 368437.9% | - | 36698.3% | 39408.4% | 1437.5% | - | - | - | 4966.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -11.1% | - | -12.9% | -17.1% | -12.5% | - | -11.8% | -9.0% | -11.1% | - |
| Return on equity | -43.2% | - | -29.2% | -35.7% | -25.0% | - | -20.5% | -15.4% | -14.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.55 | 1.06 | 2.96 | 2.88 | 2.00 | 1.10 | 1.37 | 1.48 | 0.32 | 1.85 |
| Quick ratio | 0.50 | 0.78 | 2.67 | 2.61 | 1.91 | 1.06 | 1.33 | 1.45 | 0.28 | 1.72 |
| Cash ratio | 0.45 | 0.39 | 1.94 | 2.03 | 1.73 | 0.98 | 1.25 | 1.40 | 0.22 | 1.41 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -12.9x | - | -15.8x | -21.0x | -65.0x | - | -68.6x | -75.6x | -64.1x | - |
| Equity multiplier | 3.88 | 2.76 | 2.26 | 2.09 | 2.01 | 1.86 | 1.74 | 1.72 | 1.31 | 1.30 |
| Liabilities / Assets | 0.74 | 0.64 | 0.56 | 0.52 | 0.50 | 0.46 | 0.43 | 0.42 | 0.24 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - |
| Inventory turnover | 0.00 | - | 0.00 | 0.01 | 0.13 | - | 0.00 | 0.15 | 0.16 | - |
| Days sales outstanding | 52d | - | 10d | 15d | 0d | - | - | - | 73d | - |
| Days inventory outstanding | 150996d | - | 127699d | 62349d | 2839d | - | 107232d | 2393d | 2315d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 1.6x | 1.0x | 3.0x | - | 1.5x | 1.3x | 1.5x | - |
| P / S | 52073.9x | - | 7282.4x | 2501.7x | 366.7x | - | - | - | 1587.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -99.8% | - | - | - | 412.4% | - | - | - | -57.8% | - |
| Revenue CAGR (3y) | -85.2% | - | -89.3% | -80.6% | 6.8% | - | - | - | 113.8% | - |
| Revenue CAGR (5y) | -40.3% | - | 62.4% | 57.3% | 47.5% | - | - | - | 38.4% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | 99.1% | 6.9% | 88.3% | - |
| Operating income growth (YoY) | 27.8% | - | 8.4% | -22.8% | -1.4% | - | -13.6% | -31.6% | -24.2% | - |
| Net income growth (YoY) | 25.1% | - | 20.8% | -27.9% | 0.9% | - | -24.3% | -36.0% | -31.5% | - |
| EPS growth (YoY) | 61.0% | - | 82.5% | 59.6% | 63.2% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 21.2% | - | - | - | 16.1% | - | - | - | 4.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -56.6% | -51.3% | -44.3% | -44.8% | -42.1% | -36.5% | -34.9% | -31.9% | -29.9% | -29.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$33.4K totalCOVID19 Antigen Rapid Test Kits Sales$33.4K · 100.0%
Peer comparison
Same SIC group: Computer Peripheral Equipment, NEC
Comparing Ainos against the 5 most active filers in the same SIC group.